Coherus Oncology, Inc. (CHRS) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Coherence Biosciences first quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jody Seavers, Head of Investor Relations. Please go ahead. Jody Seavers Thank you, Shannon. Good afternoon and welcome to Coheris Bioscience's first quarter 2025 earnings conference call. Joining me today to discuss our results are Denny Lamphere, Chief Executive Officer of Coheris, Brian McMichael, Chief Financial Officer, Dr. Raj Dias, Chief Medical Officer, Dr. Theresa LaValley, Chief Scientific and Development Officer, and Samir Gurkalkar, Executive Vice President, Commercial. Before we get started, I would like to remind you that today's call includes forward-looking statements regarding Coheres' current expectations about future events. These statements include, but are not limited to, the following. Expectations about repurchasing Coheres' remaining convertible notes, projections of cost savings from headcount reduction, timing for Coheris to release data from its clinical trials, and projections of future expenses. All of these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance, or achievements to differ from those implied by the forward-looking statements. These statements are ...